FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Climate Change Investigation, Innovation & Investment Company, LLC 		2. Issuer Name and Ticker or Trading Symbol

Cure Pharmaceutical Holding Corp. [ CURR ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

12 SAN RAFAEL AVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/8/2017
(Street)

BELVEDERE, CA 94920
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   (1) 7/7/2018     M    297288   A $0.886   3495932   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant   $7.00   (2) 11/8/2017     P      50000       11/8/2017   11/8/2020   Common Stock   50000   $250000   (3) 50000   D    
Warrant   $1.00   (4) 5/15/2018     P      148644   (5)      5/15/2018   5/15/2021   Common Stock   148644   $250000   (6) 198644   D    

Explanation of Responses:
(1)  Conversion of Convertible Promissory Note.
(2)  The conversion price is the lesser of $7.00 or the price per share of the latest closing of a debt or equity offering by the Issuer greater than $3,000,000.
(3)  $250,000 is the principal amount paid for both a convertible note and the warrant on November 8, 2017.
(4)  Exercise price per share equal to the lower of (a) $1.00 or (b) 125% of the price of a qualified offering, and to purchase up to a number of shares of common stock equal to 50% of the number of shares of common stock issuable upon conversion of such purchaser's note.
(5)  The number of warrant shares are equal to fifty percent (50%) of the number of shares of common stock issued upon conversion of the note at the applicable conversion price under the note converted on 7/7/2018.
(6)  $250,000 is the principal amount paid for both a convertible note and the warrant on May 15, 2018.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Climate Change Investigation, Innovation & Investment Company, LLC
12 SAN RAFAEL AVE
BELVEDERE, CA 94920
X


Signatures
/s/ James Farrell, Manager of Climate Change Investigation, Innovation and Investment Company, LLC 12/13/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Cure Pharmaceutical (PK) (USOTC:CURR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cure Pharmaceutical (PK) Charts.
Cure Pharmaceutical (PK) (USOTC:CURR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cure Pharmaceutical (PK) Charts.